bioAffinity Technologies, Inc. cash flow to debt ratio of -803.64% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

bioAffinity Technologies, Inc.'s free cash flow has decreased 27.85% from $-7.34M last year to $-9.39M, signaling decreasing performance

bioAffinity Technologies, Inc.'s debt to equity ratio is 0.38, which means that the company's assets are healthy financed, signaling financial stability.

bioAffinity Technologies, Inc.'s debt has decreased relative to shareholder equity from 0.58 last year to 0.38 today, signaling strengthened financials

bioAffinity Technologies, Inc. has a net cash position, so leverage is healthy.

bioAffinity Technologies, Inc.'s interest coverage ratio is -276.15, which means that the company struggles to meet interest obligations, signaling financial risk.

bioAffinity Technologies, Inc.'s profit margin has decreased (166.50%) in the last year from -96.56% to -257.33%, signaling decreasing performance

bioAffinity Technologies, Inc.'s short-term assets of $7.57M exceed its short-term liabilities of $2.91M

bioAffinity Technologies, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

bioAffinity Technologies, Inc.'s return on equity of -257.27%, is lower than 15.00%, indicating bad performance

bioAffinity Technologies, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

bioAffinity Technologies, Inc. has insufficient public price history to evaluate earnings stability.

bioAffinity Technologies, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

bioAffinity Technologies, Inc. has negative free cash flow, indicating cash burn

bioAffinity Technologies, Inc.'s yearly earnings has decreased 64.93% since last year from $-9.04M to $-14.91M, signaling decreasing performance

bioAffinity Technologies, Inc.'s yearly revenue has decreased 34.18% since last year from $9.36M to $6.16M, signaling decreasing performance

ROIC -237.93% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

bioAffinity Technologies, Inc.'s 3-year revenue CAGR of 986.60% is positive, indicating growing revenue over the past 3 years

bioAffinity Technologies, Inc. has insufficient public price history to evaluate revenue consistency.

bioAffinity Technologies, Inc. has insufficient public price history to evaluate ROE consistency.

bioAffinity Technologies, Inc. has insufficient data to evaluate this check.

bioAffinity Technologies, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

bioAffinity Technologies, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

bioAffinity Technologies, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

bioAffinity Technologies, Inc. has insufficient data to evaluate this check.

bioAffinity Technologies, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

bioAffinity Technologies, Inc. has a price-to-book ratio of 0.68x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

bioAffinity Technologies, Inc. has a price-to-sales ratio of 0.43x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue